Johnson & Johnson (JNJ-N)

Pays a 3.3% yield and has great drugs. Even with the talcum powder litigation, he'd buy it here.

It doesn't grow quickly, has a modest dividend and is diversified.

Concerns in pharmaceutical segment, as one particular drug facing patent cliff next year. Talc litigation still an overhang; once done, can focus on turning around core operations. Diversified, likes the pipeline. You can afford to be patient.

It is in the medical devices and pharma spaces and has spun off the consumer care division. The overhang is the talcum powder litigation. He hopes it will be settled before too long and then investors can concentrate on the growth aspect of the stock. It has set aside 8 to 10 billion dollars for a settlement.

Stock performance somewhat disappointing. She'd keep holding. After KVUE spinoff now simply a medical device, medical tech, and pharma company. Some drugs are going off patent, but successful in developing pipeline. Company still expects revenue to grow slightly as time goes on.

Very strong balance sheet, AAA credit rating. Nice dividend, increases every year. Ongoing talc litigation is the overhang, but positive steps toward resolution. Then PE multiple should lift. 

They report Tuesday. Their legal troubles could be ending, which would shift focus to their earnings. He think he will like what he sees.

He owns it partly for the defensive nature and partly for the business which leads to a focus on pharmaceuticals.

They spun off personal products, so JNJ is more a medical device company. They have huge cash from that spin-off, which could allow buying a medical device or biotech company. The talcum powder lawsuit is settling, too. They've raised their dividend for 54 years. 

It just had a major move up and whenever it does that, it sells. Pays a 3% dividend. 

Great story, he's held for a long time. Lots of growth ahead in pharma and medical devices, can make acquisitions. Very defensive. Well run. Talcum powder issues are behind them.

She's had to be patient. After spinoff of consumer division, now just pharma and medical devices. Pharma pipeline OK, needs to be replenished as with all pharma companies. Litigation overhang, hopefully resolved this year, would be a huge lift. Sticking with it for now. Attractive valuation.

Pretty defensive. AAA balance sheet. Very stable and attractive dividend, which grows. 

Talcum powder settlement offer going to plaintiffs' vote on July 26, needs 75% approval. If deal is accepted, overhang will be gone, and you have a chance to buy at cheapest valuation in 20 years at 13x PE. Now pure medical devices (huge demographic play) and pharma since the spinoff.

US drug stocks struggling, the sector has significantly weakened RSI. Can see this in JNJ chart, retesting 52-week lows, seeing lower highs. $144 is a pretty significant support level, and it's bounced off 4x already. If it bounces again, encouraging and strong support; taken out, could be really disappointing.

Healthcare is very tough to invest in, especially pharmaceuticals. Doesn't have the weight-loss drugs, underperformed. Diversified conglomerate, and competes with his holding in SYK. 

Spinoffs planned, could be interesting because you could pick the one with faster growth. Call back then and he can chat about it ;)

In line with his view of seasonality, and taking some money off the table, sell in May and go away. He's noticed that telecoms, pipelines, and healthcare are catching a bid. Why? They're solid, great balance sheets. 

A storied brand, spun off lower-margin businesses. Wonderful drugs, huge pipeline of new products, med tech. Reaffirmed earnings, he thinks they can grow at 5-10% clip. Not expensive at 14x. Great for this time of year. Great dividend yield of 3.3%.